kff glp-1 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for obesity treatment as of October 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC Insights from Specialty Physicians on

More progress on the weight-loss treatment front: A lot of pharmaceutical companies, particularly Novo Nordisk [which makes Ozempic and Wegovy] and Eli Lilly [which makes Zepbound], have been studying and reformulating oral weight-loss meds to improve how well theyre absorbed by the body, continues Corrado

Z., Yang, Y., Whiteman, M., Moore, P

Regarding hypoglycemic effects on db/db mice, t D-G1A (50 g/kg) lowered the glucose level more than b D-G1A (50 g/kg) compared with the control (35.5% vs

Their platform is not male-specific but offers more medication variety

The distinction between ingredient-level findings and product-level clinical proof applies here as it does across the broader supplement category